Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The association of anthracyclines (ANT) and paclitaxel (Tax) is one of the main treatments used in breast cancer. These treatments are known to induce severe side effects such as a decrease in overall exercise capacity (physical condition) in response to muscle and cardiorespiratory alterations. If exercise may be an effective preventive strategy, it seems important to prescribe the most efficient exercise modality. Among them, concentric cycling (i.e., classic cycling) can significantly induce metabolic stimulus, which is needed for maintaining exercise capacity. The PROTECT-07 study aims to demonstrate the superiority of a training program based on concentric cycling during chemotherapy compared to standard treatment. The duration of the training program is 15 weeks with one session per week.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Woman ≥ 18 years old

• Stage I to III breast cancer

• Patient currently planning (neo)adjuvant treatment combining anthracycline-cyclophosphamide and weekly paclitaxel (± trastuzumab)

• Affiliation to a social security system

• Able to speak, read and understand French

Locations
Other Locations
France
Hôpitaux civils de Colmar
NOT_YET_RECRUITING
Colmar
Institut de cancérologie Strasbourg Europe
RECRUITING
Strasbourg
Contact Information
Primary
Joris MALLARD, PhD
j.mallard@icans.eu
368767419
Time Frame
Start Date: 2024-05-30
Estimated Completion Date: 2027-01-13
Participants
Target number of participants: 156
Treatments
Experimental: Training group
This group of patients will perform concentric cycling training program during the chemotherapy treatment.
No_intervention: Control group
This group of patients will benefit from standard care without additional training program.
Related Therapeutic Areas
Sponsors
Leads: Institut de cancérologie Strasbourg Europe

This content was sourced from clinicaltrials.gov